Posted inDiabetes & Endocrinology Gastroenterology news
GLP‑1 Receptor Agonists Associated with Lower Fibrosis Progression in MASLD and T2DM: Target‑Trial Emulation of Real‑World Data
A target-trial emulation of 4,476 matched T2DM patients with early MASLD found GLP-1RA use was associated with a 25% lower hazard of progression to high-risk FIB‑4 versus DPP‑4i (HR 0.75); no difference was seen for hard liver outcomes.